1 November 2010 in Current Clinical Pharmacology
Nanotechnology is a multidisciplinary scientific field that deals with the formulation, preparation, characterization and application of structures, devices and systems at nanometric scale. Area of concern is interdisciplinary, but with peculiarities, among others, medicine, pharmacy, biophysics, electronics, bioengineering, and molecular biology. Interest for modern nanotechnology lies in the creation and use of structures which have new properties because of their small size as well as the possibility of using these systems to control or manipulate biological structures at nanometric or atomic level. It will open the way to diagnosis and medical treatment to molecular level. This paper covers various fundamental and applied aspects of nanotechnology, in its chapters: introduction; nanoparticles (therapeutic polymers, polymeric nanoparticles, non-polymeric nanoparticles, liposomes, nanodevices) nanofarmaceutical systems used in diagnosis and therapy, in tissue engineering; pharmacokinetics and toxicity of nanoparticulate systems. Nanoparticulate systems have the potential to constitute a new generation of drug delivery systems. By their nature, nanodevices can be used as innovative diagnostic tool for detecting and monitoring disease, also for its treatment and use in developing new drugs.
1 January 2006 in Current Clinical Pharmacology
Pharmacokinetics and drug metabolism play an important role as determinants of in vivo drug action. The CYP450 enzyme family plays a determinant role in the biotransformation of a vast number of structurally diverse drugs. Many drug interactions are a result of the inhibition or induction of CYP enzymes. The non-compartmental pharmacokinetic analysis is the most used method for analyzing data from a drug interaction study. Compartmental analysis can be also useful and sometimes more informative than non-compartmental analysis. Many efforts to reduce polypharmacy are important, and pharmacokinetic tools used to study the mechanism of drug-drug interactions may help in a better management of pharmacotherapy including the avoidance of clinically relevant drug interactions.
30 July 1997 in International Journal of Pharmaceutics
1 August 2014 in Pharmacological Reports
1 May 2010 in International Journal of Pharmaceutics